JKS vs SHLS

JKS exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic YoY EPS decline of 1548.3%. While the stock appears cheap on a Price-to-Book (0.51) and Price-to-Sales (0.02) basis, these are classic 'value trap' indicators given the negative profit margins and crashing revenue growth. The dividend is fundamentally unsustainable with a payout ratio of 388.48%, suggesting the company is returning capital it does not have. Despite bullish analyst targets, the deterministic health metrics signal a high risk of further deterioration.

SHLS exhibits a concerning fundamental health profile with a Piotroski F-Score of 3/9, indicating weak financial strength. While the company shows impressive top-line growth (38.6% YoY) and an attractive PEG ratio of 0.70, the current price of $7.16 trades at a premium to both its Graham Number ($4.02) and Intrinsic Value ($5.90). The disconnect between strong growth metrics and a deteriorating health score, coupled with consistent earnings misses in recent quarters, suggests a high-risk growth play rather than a stable value investment.